Business Wire

41. Actium BioSystems Demonstrates in Vivo Feasibility Of Its Thermal Nanomedicine Cancer Treatment
    2/26/2013

    Actium BioSystems disclosed today that its novel system platform, ACT, for selectively delivering controlled hyperthermia as an adjuvant to chemotherapy, has been validated via in vivo studies by two independent authorities, including Duke University Medical Center and a contract research facility.

42. Atossa Genetics Receives Warning Letter From The Food And Drug Administration
    2/25/2013

    Atossa Genetics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”) received a Warning Letter (“Letter”) from the FDA on February 21, 2013, regarding its Mammary Aspirate Specimen Cytology Test (MASCT) System and MASCT System Collection Test (together, the “System”).

43. FDA Approves Genentech’s Kadcyla (Ado-Trastuzumab Emtansine), The First Antibody-Drug Conjugate For Treating HER2-Positive Metastatic Breast Cancer
    2/22/2013

    Genentech, a member of the Roche Group recently announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla(ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. 

44. BioInvent Recruits New Chief Executive Officer
    1/9/2013

    BioInvent International AB recently announced that Svein Mathisen has resigned from his positions as chief executive officer of the Company and as member of the Board of Directors.

45. LipoScience Receives FDA Clearance for Vantera Clinical Analyzer
    9/5/2012

    LipoScience, Inc., an in vitro diagnostic company, announced that it has received 510(k) clearance from the FDA to market the Vantera® Clinical Analyzer, which is the first NMR analyzer designed specifically for the clinical laboratory.  

46. Baxter Initiates Phase I Clinical Trial With Anti-MIF Antibody In Patients With Solid Tumors
    9/5/2012

    Baxter International Inc. has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company’s efforts to extend its oncology portfolio with advanced biological research and development.

47. Edimer Receives FDA Fast Track Designation For Lead Compound EDI200
    6/14/2012

    Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), recently announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for EDI200, the company’s novel, proprietary, recombinant protein.

48. Eureka Genomics Awarded Multi Year Contract To Assist Military Laboratory With DNA Sequencing
    5/22/2012

    Based on collaborative work done for the past twelve months with the Armed Forces DNA Identification Laboratory (AFDIL), Eureka Genomics has been awarded a multi-year contract with AFDIL to provide forensic service support that should advance efforts to identify unknown remains from the Korean War. 

49. Bristol-Myers Squibb And Gilead Sciences Announce Licensing Agreement for Development And Commercialization Of New Fixed-Dose Combination Pill For People Living With HIV
    10/27/2011
    Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb’s protease inhibitor REYATAZ®(atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.
50. Approval Of US Pilot Clinical Trial To Evaluate AclarusDx™, The Exonhit Investigational Test For Alzheimer’s Disease Diagnosis
    10/27/2011
    Exonhit (Paris:ALEHT) announced today the Institutional Review Board (IRB) approval of Exonhit sponsored pilot clinical trial aimed at evaluating the performance of AclarusDx™, a blood based investigational diagnostic test, in US-based patients suffering from memory impairment and newly referred to a reference Memory Center for Alzheimer’s Disease (AD) diagnostic workup. This study will be conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health.